Show results for
  • Sygnature
  • News
  • Drug Discovery
  • Therapeutic Areas
  • Events
  • Vacancies
Making sure our data, and our clients’ data, remain secure

Sygnature gains ISO:27001 certification for information security

Sygnature’s efforts in ensuring cybersecurity have been recognised with ISO:27001:2013 certification. This international standard lays down best practice for the management of information security, including risk assessments, security controls, and ensuring that these remain fit-for-purpose.

Our activities were independently assessed by ACM-CCAS, verified by the United Kingdom Accreditation Service and were deemed to be compliant with ISO:27001:2013 to the highest standards. The assessment looked at the information security practices and procedures around the drug discovery projects we undertake on behalf of clients.

Having undergone an intense period of implementation and audit, Sygnature Discovery were awarded the certification having demonstrated excellence across an array of information security disciplines including the strength of our technical systems and the management processes in the protection and handling of information. This ISO:27001 certification proves we are doing this effectively, and recognises the huge effort our teams have put in to making sure we are cybersecure.

Our commitment to cybersecurity is not new. Back in 2018, we gained the Cyber Essentials Plus certification, having already been given Cyber Essentials certification two years earlier. Cyber Essentials is part of the UK Government’s national cyber security strategy to help businesses protect themselves against cyber-attacks. We continue to reassess our operations every year, and gaining ISO:27001:2013 certification is the latest step in showing that our operations, people, processes, and technology, are secure – and will remain secure.

‘We have always worked extremely hard to make sure our data, and our clients’ data, remain secure,’ says Sygnature’s COO, Jonathan Williams. ‘This certification as a testament to Sygnature Discovery’s ongoing commitment to setting and maintaining already high standards. The production of confidential information is one of our end products, so it’s great to be able to provide confidence and assurance to our customers, suppliers and staff that we have been independently accredited in this vital area.’

Latest News

View All

Sygnature Discovery completes acquisition of SB Drug…

Sygnature Discovery partners the Oncology Development Programme…

Sygnature Discovery deploys Iktos’ AI technology ‘Makya™’

Sygnature Discovery acquires Peak Proteins

Get in Touch

For more details on how we can provide innovative support to your project please use this contact form.

CTA Form

Areas of interest

Discovery Discipline
Therapeutic Areas
The information you supply will be processed in accordance with the General Data Protection Regulation (EU) 2016/679. For further details about how Sygnature Discovery collects, uses and stores personal data, please refer to our Website Privacy Notice available here.